NZ533721A - Peptides and their use for treating inflammatory conditions - Google Patents

Peptides and their use for treating inflammatory conditions

Info

Publication number
NZ533721A
NZ533721A NZ533721A NZ53372102A NZ533721A NZ 533721 A NZ533721 A NZ 533721A NZ 533721 A NZ533721 A NZ 533721A NZ 53372102 A NZ53372102 A NZ 53372102A NZ 533721 A NZ533721 A NZ 533721A
Authority
NZ
New Zealand
Prior art keywords
seq
control
peptide
protein
cells
Prior art date
Application number
NZ533721A
Other languages
English (en)
Inventor
Robert Hancock
Brett Finlay
Monish Gough Scott
Dawn Bowdish
Carrie Melissa Rosenberger
Jon-Paul Steven Powers
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Priority to NZ563261A priority Critical patent/NZ563261A/en
Publication of NZ533721A publication Critical patent/NZ533721A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
NZ533721A 2001-12-03 2002-12-02 Peptides and their use for treating inflammatory conditions NZ533721A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ563261A NZ563261A (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33663201P 2001-12-03 2001-12-03
PCT/CA2002/001830 WO2003048383A2 (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Publications (1)

Publication Number Publication Date
NZ533721A true NZ533721A (en) 2007-12-21

Family

ID=23316965

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ533721A NZ533721A (en) 2001-12-03 2002-12-02 Peptides and their use for treating inflammatory conditions
NZ563261A NZ563261A (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ563261A NZ563261A (en) 2001-12-03 2002-12-02 Effectors of innate immunity

Country Status (12)

Country Link
EP (1) EP1470249A2 (zh)
JP (1) JP2005536985A (zh)
KR (1) KR20040077669A (zh)
CN (2) CN101215601A (zh)
AU (1) AU2002365675B2 (zh)
CA (1) CA2468907A1 (zh)
HK (1) HK1075677A1 (zh)
IL (1) IL162300A0 (zh)
NZ (2) NZ533721A (zh)
SG (1) SG159382A1 (zh)
WO (1) WO2003048383A2 (zh)
ZA (1) ZA200404919B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687454B2 (en) 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
US7507787B2 (en) * 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
CN1901933A (zh) * 2003-09-12 2007-01-24 英属哥伦比亚大学 用阳离子肽刺激先天免疫的方法
WO2006005190A1 (en) * 2004-07-14 2006-01-19 Inimex Pharmaceuticals Inc. Method of screening for protection from microbial infection
WO2006137444A1 (ja) * 2005-06-22 2006-12-28 Seikagaku Corporation リポアラビノマンナンの反応性除去方法とその応用
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
US8124721B2 (en) 2005-10-04 2012-02-28 Inimex Pharmaceuticals Inc. Peptides for modulating innate immunity
NZ574758A (en) 2006-08-21 2012-03-30 Univ British Columbia Small cationic antimicrobial peptides
AU2007304847A1 (en) * 2006-10-04 2008-04-10 Inimex Pharmaceuticals, Inc. Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity
WO2009057695A1 (ja) * 2007-10-30 2009-05-07 Olympus Corporation 遺伝子解析による腺腫又はがんの検出方法
WO2010026489A1 (en) * 2008-09-05 2010-03-11 The University Of British Columbia Innate immunity modulators
WO2010042534A1 (en) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Peptides and methods of use
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc البروتينات المرتبطة بمولد المستضاد st2
KR20230119130A (ko) 2020-12-14 2023-08-16 리제너론 파마슈티칼스 인코포레이티드 인히빈 서브유닛 베타 e(inhbe) 억제제로 대사 장애 및 심혈관 질환을 치료하는 방법
WO2023063994A1 (en) * 2021-10-13 2023-04-20 Phenomune, LLC Testing methods for determination of t2r phenotype and applications thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877274A (en) * 1995-06-02 1999-03-02 University Of British Columbia Antimicrobial cationic peptides
DE19734161A1 (de) * 1997-08-07 1999-04-01 Jerini Biotools Gmbh SDF-1 - Antagonisten
US6288212B1 (en) * 1998-08-28 2001-09-11 The University Of British Columbia Anti-endotoxic, antimicrobial cationic peptides and methods of use therefor

Also Published As

Publication number Publication date
AU2002365675A1 (en) 2003-06-17
ZA200404919B (en) 2006-05-31
CA2468907A1 (en) 2003-06-12
EP1470249A2 (en) 2004-10-27
WO2003048383A3 (en) 2004-08-05
SG159382A1 (en) 2010-03-30
CN101215601A (zh) 2008-07-09
AU2002365675B2 (en) 2007-04-05
NZ563261A (en) 2008-08-29
WO2003048383A2 (en) 2003-06-12
IL162300A0 (en) 2005-11-20
CN100357324C (zh) 2007-12-26
HK1075677A1 (en) 2005-12-23
CN1615368A (zh) 2005-05-11
KR20040077669A (ko) 2004-09-06
JP2005536985A (ja) 2005-12-08

Similar Documents

Publication Publication Date Title
US7507787B2 (en) Effectors of innate immunity
AU2002365675B2 (en) Effectors of innate immunity
Hirotani et al. Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-β
US20070134261A1 (en) Effectors of innate immunity
US8715637B2 (en) Interferon-lambda 1 polypeptides
Yang et al. Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation
US7687454B2 (en) Effectors of innate immunity determination
WO1997006182A1 (en) Inhibitors of apoptosis
CA2466877C (en) Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
AU2002323255A1 (en) Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US20070190533A1 (en) Effectors of innate immunity
AU2007201885A1 (en) Effectors of innate immunity
KR20070033314A (ko) 양이온성 펩티드를 사용한 선천 면역의 자극 방법
JP2009500314A (ja) 遺伝子調節
Natarajan Characterization of chemokine CCL19 in the duck (Anas platyrhynchos)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 DEC 2015 BY COMPUTER PACKAGES INC

Effective date: 20121227

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2016 BY COMPUTER PACKAGES INC

Effective date: 20151118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2017 BY COMPUTER PACKAGES INC

Effective date: 20161118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2018 BY COMPUTER PACKAGES INC

Effective date: 20171118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2019 BY COMPUTER PACKAGES INC

Effective date: 20181120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2020 BY COMPUTER PACKAGES INC

Effective date: 20191119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211117

EXPY Patent expired